Regado Biosciences, Inc. to Present at Biotechnology Industry Organization (BIO) Investor Forum
BASKING RIDGE, N.J., Oct. 2, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced it will present at the Biotechnology Industry Organization's 12th Annual BIO Investor Forum, to be held October 8-9, 2013, at the Palace Hotel in San Francisco.
BIO Investor Forum is a national investor forum to explore investment trends and opportunities in life sciences, with a focus on venture-stage growth and emerging public companies as well as those poised to join the growth "watch list" in 2014.
David J. Mazzo, Ph.D., President and Chief Executive Officer of Regado Biosciences, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Date: | Tuesday, October 8th, 2013 | ||||
Time: | 10:30 am Pacific Daylight Time (1:30 pm EDT) | ||||
Location: | Presidio room at The Palace Hotel, San Francisco, CA | ||||
The presentation will be webcast live and will remain available for 90 days following the live presentation. To access the webcast, please visit the investor relations section of the Regado Biosciences website at http://regadobio.investorroom.com.
ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is being developed for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs. More information can be found at www.regadobio.com.
For more information on Regado's Phase 3 REGULATE-PCI clinical study, please visit:
http://www.clinicaltrials.gov/ct2/show/NCT01848106?term=Regado&rank=1
Contact:
Tiberend Strategic Advisors, Inc.
Investors - Joshua Drumm, Ph.D.
jdrumm@tiberend.com; (212) 375-2664
Media - Andrew Mielach
amielach@tiberend.com; (212) 375-2694
SOURCE Regado Biosciences, Inc.
Help employers find you! Check out all the jobs and post your resume.